Results 31 to 40 of about 52,122 (312)

Repeated activation of delta opioid receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain

Molecular Pain, 2016
Despite mu opioid receptor agonists are the cornerstones of moderate-to-severe acute pain treatment, their effectiveness in chronic pain conditions is controversial.
Nunzio Vicario PhD (cand), Rosalba Parenti PhD, Giuseppina Aricò PhD, Rita Turnaturi PhD, Giovanna Maria Scoto MS, Santina Chiechio PhD, Carmela Parenti PhD   +6 more
doaj   +1 more source

Lack of μ-Opioid Receptor-Mediated G-Protein Activation in the Spinal Cord of Mice Lacking Exon 1 or Exons 2 and 3 of the MOR-1 Gene

Journal of Pharmacological Sciences, 2003
: The G-protein activation induced by μ-opioid receptor agonists was determined in spinal cord membranes from two types of μ-opioid receptor knockout mice: mice with a disruption of exon 1 (MOR (Exon 1)-KO) or exons 2 and 3 (MOR (Exons 2 and 3)-KO) of ...
Hirokazu Mizoguchi, Hsiang-En Wu, Minoru Narita, Ichiro Sora, F. Scott Hall, George R. Uhl, Horace H. Loh, Hiroshi Nagase, Leon F. Tseng   +8 more
doaj   +1 more source

Therapeutic Potential of Kappa Opioid Agonists [PDF]

Pharmaceuticals, 2019
Many original research articles have been published that describe findings and outline areas for the development of kappa-opioid agonists (KOAs) as novel drugs; however, a single review article that summarizes the broad potential for KOAs in drug development does not exist.
Tyler C. Beck, Matthew A. Hapstack, Kyle R. Beck, Thomas A. Dix   +3 more
openaire   +3 more sources

Biochemical pharmacology of the positive allosteric modulation of the GABAb receptor "in Vitro" and "in Vivo" [PDF]

, 2007
Allosteric modulators of G-protein coupled receptors (GPCRs) interact with binding sites on the receptor molecule that are topographically distinct from the classic orthosteric site.
Gjoni, Tina
core   +1 more source

In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice

Frontiers in Pharmacology, 2018
Pain, particularly chronic pain, is still an unsolved medical condition. Central goals in pain control are to provide analgesia of adequate efficacy and to reduce complications associated with the currently available drugs.
Roberta Lattanzi, Silvia Rief, Helmut Schmidhammer, Lucia Negri, Mariana Spetea   +4 more
doaj   +1 more source

Opioid use disorder and treatment: challenges and opportunities

BMC Health Services Research, 2019
Background Addiction health service researchers have focused efforts on opioid use disorder (OUD) and strategies to address the emerging public health threats associated with the epidemics of opioid use and opioid overdose.
Kim A. Hoffman, Javier Ponce Terashima, Dennis McCarty   +2 more
doaj   +1 more source

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.

International Journal of Population Data Science, 2022
Objectives There are critical periods of mortality risk at onset and cessation of opioid agonist treatment. We aim to determine whether non-fatal overdose followed the same pattern as fatal overdose, comparing the first 4 weeks of treatment and ...
Nicola Jones, Louisa Degenhardt, Matthew Hickman, Suzanne Nielsen, Sarah Larney, Timothy Dobbins, Robert Ali   +6 more
doaj   +1 more source

INTERIM OPIOID AGONIST TREATMENT FOR OPIOID ADDICTION. A SYSTEMATIC REVIEW.

, 2020
We plan to conduct a systematic review assessing the benefits of interim opioid agonist treatment in terms of retention in treatment, access to standard opioid agonist maintenance treatment, patient satisfaction, quality of life or wellbeing, use of ...
Laura Samsó Jofra, Ivan Solà
core   +1 more source

Long‐term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox

Pharmacology Research & Perspectives, 2021
Opioid overdose is a leading cause of death in the United States. The only treatment available currently is the competitive antagonist, naloxone (Narcan®).
Joshua C. Zamora, Hudson R. Smith, Elaine M. Jennings, Teresa S. Chavera, Varun Kotipalli, Aleasha Jay, Stephen M. Husbands, Alex Disney, Kelly A. Berg, William P. Clarke   +9 more
doaj   +1 more source

Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain–Depression Comorbidity via Purinergic–Noradrenergic Signaling

Advanced Science, EarlyView.
Bone cancer pain and depression share a common origin: astrocytic A2‐to‐A1 transition in the posterior piriform cortex. This phenotypic shift disrupts the ATP–adenosine–A2AR–norepinephrine axis, simultaneously driving nociceptive and affective dysfunction.
Jiang‐Ping Liu, Jun‐Han Zhang, Zhi‐Xuan Tan, Wei‐Bing Yan, Ya‐Ru Yuan, Yao Liu, Bing‐Di Wei, Meng‐Qi Ding, Zhuo‐Min Fu, Ying Liu, An‐Qi Wang, Lin Ma, Yong‐Hong Li, Er‐Qing Chai, Chao‐Jun Wei   +14 more
wiley   +1 more source